Beta Drugs Secures NSE Mainboard Approval, to Begin Trading from November 24

Chandigarh, November 21, 2025: Beta Drugs Limited (BETA) has received approval to migrate its equity shares from the NSE SME Emerge platform to the NSE Mainboard, marking a significant shift in its capital market presence. Trading on the Mainboard will begin on Monday, 24 November 2025.

As of today, Beta Drugs Limited share price was trading at ₹1,659.90, up 1.64% from the previous close of ₹1,633.05 on the NSE. The stock opened at ₹1,615 and has so far touched an intraday high of ₹1,665, with a low of ₹1,602.10.

NSE Approves Listing of Over 1 Crore Equity Shares

According to Beta Drugs, the company has received approval to list its 1,00,94,553 fully paid-up equity shares on the NSE Mainboard. The move follows a written communication from the exchange dated 20 November, confirming the company’s migration from the NSE SME Emerge platform. The shift enables trading of the company’s shares on the main capital market segment, allowing wider market participation and improved liquidity.

Securities Details Provided By Exchange

The exchange has listed 1,00,94,553 fully paid-up equity shares of Beta Drugs, each with a face value of ₹10, in the EQ series under the symbol BETA. The market lot is 1 share, and the distinctive numbers range from 1 to 1,00,94,553, covering the company’s entire share capital.

Corporate Communication

In the official notice, Beta Drugs stated that the shares will be actively listed and traded on the NSE Mainboard as of November 24, 2025, and that trading on the SME Emerge platform would be suspended as of the same date. Rajni Brar, the Company Secretary, received the confirmation letter.

Strategic Context

Migration to the NSE Mainboard is generally viewed as a step that increases market visibility, attracts a broader base of institutional participants, and supports long-term capital access. Beta Drugs noted that the shift is expected to aid investor confidence and improve liquidity as the company enters its next phase of expansion.

REF: https://nsearchives.nseindia.com/corporate/BETA_21112025085523_migration_letter.pdf

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations